glutaminase and Leiomyomatosis

Hereditary leiomyomatosis and renal cell carcinoma (HLRCC) is characterized by germline mutations of the FH gene that encodes for the TCA cycle enzyme, fumarate hydratase. HLRCC patients are at risk for the development of an aggressive form of type 2 papillary renal cell carcinoma. By studying the mechanism of action of marizomib, a proteasome inhibitor able to cross the blood-brain barrier, we found that it modulates the metabolism of HLRCC cells. Marizomib decreased glycolysis in vitro and in vivo by downregulating p62 and c-Myc. C-Myc downregulation decreased the expression of lactate dehydrogenase A, the enzyme catalyzing the conversion of pyruvate to lactate. In addition, proteasomal inhibition lowered the expression of the glutaminases GLS and GLS2, which support glutamine metabolism and the maintenance of the redox balance. Thus, in HLRCC cells, proteasome inhibition disrupts glucose and glutamine metabolism, restricting nutrients and lowering the cells' anti-oxidant response capacity. Although the cytotoxicity induced by proteasome inhibitors is complex, the understanding of their metabolic effects in HLRCC may lead to the development of effective therapeutic strategies or to the development of markers of efficacy.

Topics: Animals; Carcinoma, Renal Cell; Cell Line, Tumor; Female; Fumarate Hydratase; Gene Expression Regulation, Neoplastic; Germ-Line Mutation; Glutaminase; Glycolysis; Humans; Kidney Neoplasms; Lactate Dehydrogenase 5; Lactones; Leiomyomatosis; Mice; Mice, Nude; Neoplastic Syndromes, Hereditary; Proteasome Endopeptidase Complex; Proteasome Inhibitors; Proto-Oncogene Proteins c-myc; Pyrroles; Sequestosome-1 Protein; Signal Transduction; Skin Neoplasms; Uterine Neoplasms; Xenograft Model Antitumor Assays